{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:09:14Z","timestamp":1772028554728,"version":"3.50.1"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00284-026-04725-4","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:29:55Z","timestamp":1770290995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches"],"prefix":"10.1007","volume":"83","author":[{"given":"Prashant","family":"Tiwari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istuti","family":"Saraswat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"11","key":"4725_CR1","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMra031087","volume":"350","author":"D Ganem","year":"2004","unstructured":"Ganem D, Prince AM (2004) Hepatitis B virus infection\u2013natural history and clinical consequences. N Engl J Med 350(11):1118\u20131129","journal-title":"N Engl J Med"},{"issue":"8","key":"4725_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"Y-C Hsu","year":"2023","unstructured":"Hsu Y-C, Huang DQ, Nguyen MH (2023) Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol 20(8):524\u2013537","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4725_CR3","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81070","author":"E Martyn","year":"2023","unstructured":"Martyn E et al (2023) The forgotten people: hepatitis B virus (HBV) infection as a priority for the inclusion health agenda. Elife. https:\/\/doi.org\/10.7554\/eLife.81070","journal-title":"Elife"},{"key":"4725_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11051140","author":"D di Filippo Villa","year":"2023","unstructured":"di Filippo Villa D, Navas MC (2023) Vertical transmission of hepatitis B virus-an update. Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms11051140","journal-title":"Microorganisms"},{"key":"4725_CR5","doi-asserted-by":"publisher","first-page":"104925","DOI":"10.1016\/j.antiviral.2020.104925","volume":"182","author":"S Tsukuda","year":"2020","unstructured":"Tsukuda S, Watashi K (2020) Hepatitis B virus biology and life cycle. Antiviral Res 182:104925","journal-title":"Antiviral Res"},{"issue":"10003","key":"4725_CR6","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A et al (2015) Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386(10003):1546\u20131555","journal-title":"Lancet"},{"issue":"4","key":"4725_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","volume":"12","author":"R Gish","year":"2012","unstructured":"Gish R et al (2012) Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 12(4):341\u2013353","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"4725_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/biom15010062","volume":"15","author":"A Boonstra","year":"2025","unstructured":"Boonstra A, Sari G (2025) HBV cccdna: the molecular reservoir of hepatitis B persistence and challenges to achieve viral eradication. Biomolecules 15(1):62","journal-title":"Biomolecules"},{"issue":"1","key":"4725_CR9","doi-asserted-by":"publisher","first-page":"e1232","DOI":"10.1002\/cti2.1232","volume":"10","author":"DT Jansen","year":"2021","unstructured":"Jansen DT et al (2021) Designing the next-generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures. Clin Transl Immunol 10(1):e1232","journal-title":"Clin Transl Immunol"},{"key":"4725_CR10","doi-asserted-by":"publisher","first-page":"1437502","DOI":"10.3389\/fpubh.2024.1437502","volume":"12","author":"F Borondy-Jenkins","year":"2024","unstructured":"Borondy-Jenkins F et al (2024) Global hepatitis B and D community advisory board: expectations, challenges, and lessons learned. Front Public Health 12:1437502","journal-title":"Front Public Health"},{"key":"4725_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fcimb.2024.1356003","volume":"14","author":"M Naderi","year":"2024","unstructured":"Naderi M et al (2024) An overview of anti-Hepatitis B virus flavonoids and their mechanisms of action. Front Cell Infect Microbiol 14:135\u20136003","journal-title":"Front Cell Infect Microbiol"},{"issue":"18","key":"4725_CR12","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.1073\/pnas.86.18.7059","volume":"86","author":"E Orito","year":"1989","unstructured":"Orito E et al (1989) Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc Natl Acad Sci U S A 86(18):7059\u20137062","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4725_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bpg.2017.04.010","volume":"31","author":"C-L Lin","year":"2017","unstructured":"Lin C-L, Kao J-H (2017) Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol 31(3):249\u2013255","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"4725_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/genomeA.01075-14","author":"S Hern\u00e1ndez","year":"2014","unstructured":"Hern\u00e1ndez S et al (2014) Full-genome sequence of a hepatitis B virus genotype f1b clone from a chronically infected chilean patient. Genome Announc. https:\/\/doi.org\/10.1128\/genomeA.01075-14","journal-title":"Genome Announc"},{"issue":"Suppl 1","key":"4725_CR15","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/S1386-6532(05)80015-0","volume":"34","author":"M Buti","year":"2005","unstructured":"Buti M et al (2005) Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. J Clin Virol 34(Suppl 1):S79\u201382","journal-title":"J Clin Virol"},{"issue":"4","key":"4725_CR16","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1073\/pnas.78.4.2606","volume":"78","author":"AM Moriarty","year":"1981","unstructured":"Moriarty AM et al (1981) Expression of the hepatitis B virus surface antigen gene in cell culture by using a Simian virus 40 vector. Proc Natl Acad Sci U S A 78(4):2606\u20132610","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5475","key":"4725_CR17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/251540a0","volume":"251","author":"SZ Hirschman","year":"1974","unstructured":"Hirschman SZ, Gerber M, Garfinkel E (1974) DNA purified from naked intranuclear particles of human liver infected with hepatitis B virus. Nature 251(5475):540\u2013542","journal-title":"Nature"},{"key":"4725_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/v15030642","author":"MA Mendenhall","year":"2023","unstructured":"Mendenhall MA, Hong X, Hu J (2023) Hepatitis B virus capsid: the core in productive entry and covalently closed circular DNA formation. Viruses. https:\/\/doi.org\/10.3390\/v15030642","journal-title":"Viruses"},{"issue":"24","key":"4725_CR19","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.3748\/wjg.v21.i24.7400","volume":"21","author":"R Toita","year":"2015","unstructured":"Toita R et al (2015) Applications of human hepatitis B virus pres domain in bio- and nanotechnology. World J Gastroenterol 21(24):7400\u20137411","journal-title":"World J Gastroenterol"},{"key":"4725_CR20","doi-asserted-by":"publisher","unstructured":"Hong X, Luckenbaugh L, Mendenhall M, Walsh R, Cabuang L, Soppe S, Revill PA, BurdetteD, Feierbach B, Delaney W, Hu J (2021) Characterization of Hepatitis B Precore\/Core-Related Antigens. JVirol. 2021 Jan 13;95(3):e01695\u201320. https:\/\/doi.org\/10.1128\/JVI.01695-20. PMID: 33148795; PMCID:PMC7925093. Page no. e01695\u201320","DOI":"10.1128\/JVI.01695-20"},{"key":"4725_CR21","first-page":"163","volume":"2","author":"RJ Lamontagne","year":"2016","unstructured":"Lamontagne RJ, Bagga S, Bouchard MJ (2016) Hepatitis B Virus Mol Biology Pathogenesis Hepatoma Res 2:163\u2013186","journal-title":"Hepatitis B Virus Mol Biology Pathogenesis Hepatoma Res"},{"issue":"11","key":"4725_CR22","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/j.1462-5822.2009.01363.x","volume":"11","author":"R Patient","year":"2009","unstructured":"Patient R, Hourioux C, Roingeard (2009) Morphogenesis of hepatitis B virus and its subviral envelope particles. Cell Microbiol 11(11):1561\u20131570","journal-title":"Cell Microbiol"},{"key":"4725_CR23","doi-asserted-by":"publisher","first-page":"104824","DOI":"10.1016\/j.antiviral.2020.104824","volume":"180","author":"Y Xia","year":"2020","unstructured":"Xia Y, Guo H (2020) Hepatitis B virus cccdna: Formation, regulation and therapeutic potential. Antiviral Res 180:104824","journal-title":"Antiviral Res"},{"issue":"1","key":"4725_CR24","first-page":"262","volume":"19","author":"CL Zheng","year":"2019","unstructured":"Zheng CL et al (2019) Hepatitis B virus core protein dimer\u2013dimer interface is critical for viral replication. Mol Med Rep 19(1):262\u2013270","journal-title":"Mol Med Rep"},{"issue":"3","key":"4725_CR25","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1128\/JVI.73.3.1885-1893.1999","volume":"73","author":"RE Lanford","year":"1999","unstructured":"Lanford RE et al (1999) Mapping of the hepatitis B virus reverse transcriptase TP and RT domains by transcomplementation for nucleotide priming and by protein-protein interaction. J Virol 73(3):1885\u20131893","journal-title":"J Virol"},{"issue":"9","key":"4725_CR26","doi-asserted-by":"publisher","first-page":"e0005122","DOI":"10.1128\/jvi.00051-22","volume":"96","author":"C Pley","year":"2022","unstructured":"Pley C et al (2022) Spacer domain in hepatitis B virus polymerase: plugging a hole or performing a role? J Virol 96(9):e0005122","journal-title":"J Virol"},{"key":"4725_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.antiviral.2015.09.011","volume":"123","author":"DN Clark","year":"2015","unstructured":"Clark DN, Hu J (2015) Hepatitis B virus reverse transcriptase - target of current antiviral therapy and future drug development. Antiviral Res 123:132\u2013137","journal-title":"Antiviral Res"},{"issue":"3","key":"4725_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41594-023-01191-5","volume":"31","author":"J Asami","year":"2024","unstructured":"Asami J et al (2024) Structural basis of hepatitis B virus receptor binding. Nat Struct Mol Biol 31(3):447\u2013454","journal-title":"Nat Struct Mol Biol"},{"key":"4725_CR29","doi-asserted-by":"crossref","unstructured":"Herrscher C, Roingeard, Blanchard E (2020) Hepatitis B virus entry into cells. Cells, 9(6) : 1486","DOI":"10.3390\/cells9061486"},{"issue":"3","key":"4725_CR30","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/hep.26125","volume":"57","author":"C Sureau","year":"2013","unstructured":"Sureau C, Salisse J (2013) A conformational Heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology 57(3):985\u2013994","journal-title":"Hepatology"},{"issue":"1","key":"4725_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/hep.28013","volume":"63","author":"ER Verrier","year":"2016","unstructured":"Verrier ER et al (2016) A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. Hepatology 63(1):35\u201348","journal-title":"Hepatology"},{"issue":"3","key":"4725_CR32","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/S0021-9258(17)49936-4","volume":"295","author":"M Iwamoto","year":"2020","unstructured":"Iwamoto M et al (2020) The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network. J Biol Chem 295(3):800\u2013807","journal-title":"J Biol Chem"},{"issue":"23","key":"4725_CR33","doi-asserted-by":"publisher","first-page":"12443","DOI":"10.1128\/JVI.01594-09","volume":"83","author":"Y Le Duff","year":"2009","unstructured":"Le Duff Y, Blanchet M, Sureau C (2009) The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent. J Virol 83(23):12443\u201312451","journal-title":"J Virol"},{"issue":"17","key":"4725_CR34","doi-asserted-by":"publisher","first-page":"8487","DOI":"10.1073\/pnas.1811064116","volume":"116","author":"M Iwamoto","year":"2019","unstructured":"Iwamoto M et al (2019) Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. Proc Natl Acad Sci U S A 116(17):8487\u20138492","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"4725_CR35","doi-asserted-by":"publisher","first-page":"e0093821","DOI":"10.1128\/JVI.00938-21","volume":"95","author":"K Fukano","year":"2021","unstructured":"Fukano K et al (2021) NTCP oligomerization occurs downstream of the NTCP-EGFR interaction during hepatitis B virus internalization. J Virol 95(24):e0093821","journal-title":"J Virol"},{"issue":"1","key":"4725_CR36","doi-asserted-by":"publisher","first-page":"14349","DOI":"10.1038\/s41598-020-71453-5","volume":"10","author":"S-W Chen","year":"2020","unstructured":"Chen S-W et al (2020) Modulation of hepatitis B virus infection by epidermal growth factor secreted from liver sinusoidal endothelial cells. Sci Rep 10(1):14349","journal-title":"Sci Rep"},{"key":"4725_CR37","first-page":"20","volume":"14","author":"T Umetsu","year":"2018","unstructured":"Umetsu T et al (2018) Inhibitory effect of Silibinin on hepatitis B virus entry. Biochem Biophys Rep 14:20\u201325","journal-title":"Biochem Biophys Rep"},{"issue":"8","key":"4725_CR38","doi-asserted-by":"publisher","first-page":"e13205","DOI":"10.1111\/cmi.13205","volume":"22","author":"C Herrscher","year":"2020","unstructured":"Herrscher C et al (2020) Hepatitis B virus entry into HepG2-NTCP cells requires clathrin\u2010mediated endocytosis. Cell Microbiol 22(8):e13205","journal-title":"Cell Microbiol"},{"issue":"2","key":"4725_CR39","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1128\/jvi.71.2.1310-1316.1997","volume":"71","author":"M Kann","year":"1997","unstructured":"Kann M, Bischof A, Gerlich WH (1997) In vitro model for the nuclear transport of the hepadnavirus genome. J Virol 71(2):1310\u20131316","journal-title":"J Virol"},{"issue":"1 Suppl","key":"4725_CR40","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jhep.2016.02.008","volume":"64","author":"ML Blondot","year":"2016","unstructured":"Blondot ML, Bruss V, Kann M (2016) Intracellular transport and egress of hepatitis B virus. J Hepatol 64(1 Suppl):S49\u2013S59","journal-title":"J Hepatol"},{"key":"4725_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/v12070738","author":"H de Rocquigny","year":"2020","unstructured":"de Rocquigny H et al (2020) Phosphorylation of the arginine-rich C-terminal domains of the hepatitis B virus (HBV) core protein as a fine regulator of the interaction between HBc and nucleic acid. Viruses. https:\/\/doi.org\/10.3390\/v12070738","journal-title":"Viruses"},{"issue":"2","key":"4725_CR42","doi-asserted-by":"publisher","first-page":"eadi7606","DOI":"10.1126\/sciadv.adi7606","volume":"10","author":"R Yang","year":"2024","unstructured":"Yang R et al (2024) Structural basis for nuclear import of hepatitis B virus (HBV) nucleocapsid core. Sci Adv 10(2):eadi7606","journal-title":"Sci Adv"},{"key":"4725_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/v13050757","author":"J Diogo Dias","year":"2021","unstructured":"Diogo Dias J, Sarica N, Neuveut C (2021) Early steps of hepatitis B life cycle: from capsid nuclear import to cccDNA formation. Viruses. https:\/\/doi.org\/10.3390\/v13050757","journal-title":"Viruses"},{"key":"4725_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/v13081463","author":"L Wei","year":"2021","unstructured":"Wei L, Ploss A (2021) Mechanism of hepatitis B virus cccDNA formation. Viruses. https:\/\/doi.org\/10.3390\/v13081463","journal-title":"Viruses"},{"issue":"1","key":"4725_CR45","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s41467-021-21850-9","volume":"12","author":"L Wei","year":"2021","unstructured":"Wei L, Ploss A (2021) Hepatitis B virus cccDNA is formed through distinct repair processes of each strand. Nat Commun 12(1):1591","journal-title":"Nat Commun"},{"issue":"40","key":"4725_CR46","doi-asserted-by":"publisher","first-page":"E4244","DOI":"10.1073\/pnas.1409986111","volume":"111","author":"C Koniger","year":"2014","unstructured":"Koniger C et al (2014) Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A 111(40):E4244\u2013E4253","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"4725_CR47","doi-asserted-by":"publisher","first-page":"e1007124","DOI":"10.1371\/journal.ppat.1007124","volume":"14","author":"K Kitamura","year":"2018","unstructured":"Kitamura K et al (2018) Flap endonuclease 1 is involved in CccDNA formation in the hepatitis B virus. PLoS Pathog 14(6):e1007124","journal-title":"PLoS Pathog"},{"issue":"5","key":"4725_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41564-020-0678-0","volume":"5","author":"L Wei","year":"2020","unstructured":"Wei L, Ploss A (2020) Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation. Nat Microbiol 5(5):715\u2013726","journal-title":"Nat Microbiol"},{"issue":"10","key":"4725_CR49","doi-asserted-by":"publisher","first-page":"e1005893","DOI":"10.1371\/journal.ppat.1005893","volume":"12","author":"Y Qi","year":"2016","unstructured":"Qi Y et al (2016) DNA polymerase kappa is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus. PLoS Pathog 12(10):e1005893","journal-title":"PLoS Pathog"},{"issue":"4","key":"4725_CR50","doi-asserted-by":"publisher","first-page":"e1007742","DOI":"10.1371\/journal.ppat.1007742","volume":"15","author":"L Tang","year":"2019","unstructured":"Tang L et al (2019) DNA polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA. PLoS Pathog 15(4):e1007742","journal-title":"PLoS Pathog"},{"key":"4725_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02230-18","author":"M Sheraz","year":"2019","unstructured":"Sheraz M et al (2019) Cellular DNA topoisomerases are required for the synthesis of hepatitis B virus covalently closed circular DNA. J Virol. https:\/\/doi.org\/10.1128\/JVI.02230-18","journal-title":"J Virol"},{"issue":"8","key":"4725_CR52","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.celrep.2017.08.008","volume":"20","author":"W Daddacha","year":"2017","unstructured":"Daddacha W et al (2017) SAMHD1 promotes DNA end resection to facilitate DNA repair by homologous recombination. Cell Rep 20(8):1921\u20131935","journal-title":"Cell Rep"},{"issue":"12","key":"4725_CR53","doi-asserted-by":"publisher","first-page":"e1006784","DOI":"10.1371\/journal.ppat.1006784","volume":"13","author":"Q Long","year":"2017","unstructured":"Long Q et al (2017) The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation. PLoS Pathog 13(12):e1006784","journal-title":"PLoS Pathog"},{"issue":"6","key":"4725_CR54","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/nar\/gkr1024","volume":"40","author":"H Arakawa","year":"2012","unstructured":"Arakawa H et al (2012) Functional redundancy between DNA ligases I and III in DNA replication in vertebrate cells. Nucleic Acids Res 40(6):2599\u20132610","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"4725_CR55","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.str.2004.09.018","volume":"12","author":"JB Bruning","year":"2004","unstructured":"Bruning JB, Shamoo Y (2004) Structural and thermodynamic analysis of human PCNA with peptides derived from DNA polymerase-delta p66 subunit and flap endonuclease-1. Structure 12(12):2209\u20132219","journal-title":"Structure"},{"issue":"1","key":"4725_CR56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1006\/jmbi.2000.4481","volume":"307","author":"CT Bock","year":"2001","unstructured":"Bock CT et al (2001) Structural organization of the hepatitis B virus minichromosome. J Mol Biol 307(1):183\u2013196","journal-title":"J Mol Biol"},{"issue":"20","key":"4725_CR57","doi-asserted-by":"publisher","first-page":"11673","DOI":"10.1093\/nar\/gkx771","volume":"45","author":"TS Rai","year":"2017","unstructured":"Rai TS et al (2017) Histone chaperone HIRA deposits histone H3.3 onto foreign viral DNA and contributes to anti-viral intrinsic immunity. Nucleic Acids Res 45(20):11673\u201311683","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4725_CR58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cell.2013.08.029","volume":"155","author":"S Adam","year":"2013","unstructured":"Adam S, Polo SE, Almouzni G (2013) Transcription recovery after DNA damage requires chromatin priming by the H3.3 histone chaperone HIRA. Cell 155(1):94\u2013106","journal-title":"Cell"},{"issue":"42","key":"4725_CR59","doi-asserted-by":"publisher","first-page":"E5715","DOI":"10.1073\/pnas.1518090112","volume":"112","author":"P Tropberger","year":"2015","unstructured":"Tropberger P et al (2015) Mapping of histone modifications in episomal HBV CccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci U S A 112(42):E5715\u2013E5724","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4725_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/v10110603","author":"V Meier-Stephenson","year":"2018","unstructured":"Meier-Stephenson V et al (2018) Comprehensive analysis of hepatitis B virus promoter region mutations. Viruses. https:\/\/doi.org\/10.3390\/v10110603","journal-title":"Viruses"},{"issue":"47","key":"4725_CR61","doi-asserted-by":"publisher","first-page":"19975","DOI":"10.1073\/pnas.0908365106","volume":"106","author":"L Belloni","year":"2009","unstructured":"Belloni L et al (2009) Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of CccDNA function. Proc Natl Acad Sci U S A 106(47):19975\u201319979","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4725_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/v9040069","author":"CM Livingston","year":"2017","unstructured":"Livingston CM et al (2017) Identifying and characterizing interplay between hepatitis B virus X protein and Smc5\/6. Viruses. https:\/\/doi.org\/10.3390\/v9040069","journal-title":"Viruses"},{"issue":"5415","key":"4725_CR63","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1126\/science.284.5415.825","volume":"284","author":"LG Guidotti","year":"1999","unstructured":"Guidotti LG et al (1999) Viral clearance without destruction of infected cells during acute HBV infection. Science 284(5415):825\u2013829","journal-title":"Science"},{"issue":"4","key":"4725_CR64","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1073\/pnas.98.4.1841","volume":"98","author":"H Tang","year":"2001","unstructured":"Tang H, McLachlan A (2001) Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl Acad Sci U S A 98(4):1841\u20131846","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4725_CR65","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1038\/s41467-018-06739-4","volume":"9","author":"P Moreau","year":"2018","unstructured":"Moreau P et al (2018) Tridimensional infiltration of DNA viruses into the host genome shows Preferential contact with active chromatin. Nat Commun 9(1):4268","journal-title":"Nat Commun"},{"issue":"4","key":"4725_CR66","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1016-8478(23)17616-3","volume":"25","author":"HJ Lee","year":"2008","unstructured":"Lee HJ et al (2008) Polyadenylation is dispensable for encapsidation and reverse transcription of hepatitis B viral pregenomic RNA. Mol Cells 25(4):545\u2013552","journal-title":"Mol Cells"},{"key":"4725_CR67","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.antiviral.2017.11.009","volume":"149","author":"T Zhou","year":"2018","unstructured":"Zhou T et al (2018) HBsAg mRNA degradation induced by a Dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element. Antiviral Res 149:191\u2013201","journal-title":"Antiviral Res"},{"issue":"10","key":"4725_CR68","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1016\/j.celrep.2019.10.113","volume":"29","author":"A Hyrina","year":"2019","unstructured":"Hyrina A et al (2019) A Genome-wide CRISPR screen identifies ZCCHC14 as a host factor required for hepatitis B surface antigen production. Cell Rep 29(10):2970\u20132978 e6","journal-title":"Cell Rep"},{"issue":"6","key":"4725_CR69","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41594-020-0427-3","volume":"27","author":"D Kim","year":"2020","unstructured":"Kim D et al (2020) Viral hijacking of the TENT4-ZCCHC14 complex protects viral RNAs via mixed tailing. Nat Struct Mol Biol 27(6):581\u2013588","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"4725_CR70","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/nar\/gki251","volume":"33","author":"A Chen","year":"2005","unstructured":"Chen A, Kao YF, Brown CM (2005) Translation of the first upstream ORF in the hepatitis B virus pregenomic RNA modulates translation at the core and polymerase initiation codons. Nucleic Acids Res 33(4):1169\u20131181","journal-title":"Nucleic Acids Res"},{"key":"4725_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2105-7-75","volume":"7","author":"AE Firth","year":"2006","unstructured":"Firth AE, Brown CM (2006) Detecting overlapping coding sequences in virus genomes. BMC Bioinformatics 7:75","journal-title":"BMC Bioinformatics"},{"issue":"25","key":"4725_CR72","doi-asserted-by":"publisher","first-page":"7993","DOI":"10.3748\/wjg.v20.i25.7993","volume":"20","author":"A Chen","year":"2014","unstructured":"Chen A, Panjaworayan TTN, Brown CM (2014) Prospects for inhibiting the post-transcriptional regulation of gene expression in hepatitis B virus. World J Gastroenterol 20(25):7993\u20138004","journal-title":"World J Gastroenterol"},{"key":"4725_CR73","doi-asserted-by":"crossref","unstructured":"Prifti GM et al (2021) Recent advances in hepatitis B treatment. Pharmaceuticals (Basel), 14(5): 417","DOI":"10.3390\/ph14050417"},{"key":"4725_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/v9030056","author":"J Hu","year":"2017","unstructured":"Hu J, Liu K (2017) Complete and incomplete hepatitis B virus particles: formation, function, and application. Viruses. https:\/\/doi.org\/10.3390\/v9030056","journal-title":"Viruses"},{"key":"4725_CR75","doi-asserted-by":"crossref","unstructured":"Selzer L, Zlotnick A (2015) Assembly and release of hepatitis B virus. Cold Spring Harb Perspect Med, 5(12):a021394","DOI":"10.1101\/cshperspect.a021394"},{"key":"4725_CR76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.coviro.2021.04.009","volume":"49","author":"G Ligat","year":"2021","unstructured":"Ligat G et al (2021) Hepatitis B virus-host interactions and novel targets for viral cure. Curr Opin Virol 49:41\u201351","journal-title":"Curr Opin Virol"},{"issue":"5","key":"4725_CR77","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/hep.24555","volume":"54","author":"YF Liaw","year":"2011","unstructured":"Liaw YF et al (2011) Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 54(5):1591\u20131599","journal-title":"Hepatology"},{"issue":"2","key":"4725_CR78","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) Electronic address, e.e.e. And L. European association for the study of the, EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 67(2):370\u2013398","journal-title":"J Hepatol"},{"issue":"8","key":"4725_CR79","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"Boni C et al (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81(8):4215\u20134225","journal-title":"J Virol"},{"issue":"1","key":"4725_CR80","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/1743-422X-10-239","volume":"10","author":"WH Gerlich","year":"2013","unstructured":"Gerlich WH (2013) Medical virology of hepatitis B: how it began and where we are now. Virol J 10(1):239","journal-title":"Virol J"},{"issue":"6","key":"4725_CR81","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/hep.29348","volume":"66","author":"X Cheng","year":"2017","unstructured":"Cheng X et al (2017) Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages. Hepatology 66(6):1779\u20131793","journal-title":"Hepatology"},{"issue":"7","key":"4725_CR82","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1053\/j.gastro.2011.02.057","volume":"140","author":"M Lutgehetmann","year":"2011","unstructured":"Lutgehetmann M et al (2011) Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 140(7):2074\u20132083","journal-title":"Gastroenterology"},{"issue":"6","key":"4725_CR83","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1053\/j.gastro.2018.01.034","volume":"154","author":"A Suslov","year":"2018","unstructured":"Suslov A et al (2018) Hepatitis B virus does not interfere with innate immune responses in the human liver. Gastroenterology 154(6):1778\u20131790","journal-title":"Gastroenterology"},{"issue":"6176","key":"4725_CR84","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1126\/science.1243462","volume":"343","author":"J Lucifora","year":"2014","unstructured":"Lucifora J et al (2014) Specific and nonhepatotoxic degradation of nuclear hepatitis B virus CccDNA. Science 343(6176):1221\u20131228","journal-title":"Science"},{"issue":"1","key":"4725_CR85","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.bbrc.2016.03.082","volume":"473","author":"F Xu","year":"2016","unstructured":"Xu F et al (2016) HBsAg blocks TYPE I IFN induced up-regulation of A3G through Inhibition of STAT3. Biochem Biophys Res Commun 473(1):219\u2013223","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"4725_CR86","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.4049\/jimmunol.1201625","volume":"190","author":"S Wang","year":"2013","unstructured":"Wang S et al (2013) Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes\/macrophages by interfering with JNK activation. J Immunol 190(10):5142\u20135151","journal-title":"J Immunol"},{"issue":"13","key":"4725_CR87","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.molimm.2009.04.031","volume":"46","author":"Y Xu","year":"2009","unstructured":"Xu Y et al (2009) HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol 46(13):2640\u20132646","journal-title":"Mol Immunol"},{"key":"4725_CR88","doi-asserted-by":"publisher","first-page":"104816","DOI":"10.1016\/j.antiviral.2020.104816","volume":"179","author":"A Kuipery","year":"2020","unstructured":"Kuipery A, Gehring AJ, Isogawa M (2020) Mechanisms of HBV immune evasion. Antiviral Res 179:104816","journal-title":"Antiviral Res"},{"issue":"2","key":"4725_CR89","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2174\/187152609787847677","volume":"9","author":"LL Stein","year":"2009","unstructured":"Stein LL, Loomba R (2009) Drug targets in hepatitis B virus infection. Infect Disord Drug Targets 9(2):105\u2013116","journal-title":"Infect Disord Drug Targets"},{"issue":"4","key":"4725_CR90","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jhep.2016.11.009","volume":"66","author":"S Shimura","year":"2017","unstructured":"Shimura S et al (2017) Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol 66(4):685\u2013692","journal-title":"J Hepatol"},{"issue":"4","key":"4725_CR91","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","volume":"60","author":"S Nkongolo","year":"2014","unstructured":"Nkongolo S et al (2014) Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 60(4):723\u2013731","journal-title":"J Hepatol"},{"issue":"1","key":"4725_CR92","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1038\/s41467-024-46706-w","volume":"15","author":"H Liu","year":"2024","unstructured":"Liu H et al (2024) Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP. Nat Commun 15(1):2476","journal-title":"Nat Commun"},{"issue":"2","key":"4725_CR93","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1056\/NEJMoa2314134","volume":"391","author":"T Asselah","year":"2024","unstructured":"Asselah T et al (2024) Bulevirtide combined with pegylated interferon for chronic hepatitis D. N Engl J Med 391(2):133\u2013143","journal-title":"N Engl J Med"},{"key":"4725_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223531","author":"P Ferenci","year":"2022","unstructured":"Ferenci P, Reiberger T, Jachs M (2022) Treatment of chronic hepatitis D with bulevirtide-a fight against two foes-an update. Cells. https:\/\/doi.org\/10.3390\/cells11223531","journal-title":"Cells"},{"issue":"3","key":"4725_CR95","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.gtc.2010.08.012","volume":"39","author":"C Hongthanakorn","year":"2010","unstructured":"Hongthanakorn C, Lok AS (2010) New pharmacologic therapies in chronic hepatitis B. Gastroenterol Clin North Am 39(3):659\u2013680","journal-title":"Gastroenterol Clin North Am"},{"issue":"3","key":"4725_CR96","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2217\/fvl.14.113","volume":"10","author":"DN Clark","year":"2015","unstructured":"Clark DN, Hu J (2015) Unveiling the roles of HBV polymerase for new antiviral strategies. Future Virol 10(3):283\u2013295","journal-title":"Future Virol"},{"key":"4725_CR97","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00836-20","author":"KE Squires","year":"2020","unstructured":"Squires KE et al (2020) ATI-2173, a novel liver-targeted non-chain-terminating nucleotide for hepatitis B virus cure regimens. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00836-20","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4725_CR98","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3350\/cmh.2021.0093","volume":"28","author":"SW Kim","year":"2022","unstructured":"Kim SW et al (2022) Toward a complete cure for chronic hepatitis B: novel therapeutic targets for hepatitis B virus. Clin Mol Hepatol 28(1):17\u201330","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"4725_CR99","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jvh.13753","volume":"30","author":"KE Squires","year":"2023","unstructured":"Squires KE et al (2023) A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infection. J Viral Hepat 30(1):19\u201328","journal-title":"J Viral Hepat"},{"issue":"23","key":"4725_CR100","doi-asserted-by":"publisher","first-page":"11945","DOI":"10.1128\/JVI.01855-15","volume":"89","author":"M Kaneko","year":"2015","unstructured":"Kaneko M et al (2015) A novel tricyclic Polyketide, Vanitaracin A, specifically inhibits the entry of hepatitis B and D viruses by targeting sodium taurocholate cotransporting polypeptide. J Virol 89(23):11945\u201311953","journal-title":"J Virol"},{"issue":"4","key":"4725_CR101","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/095632020901900404","volume":"19","author":"Y Zhu","year":"2009","unstructured":"Zhu Y et al (2009) Anti-hepatitis B virus activity in vitro of combinations of Tenofovir with nucleoside\/nucleotide analogues. Antivir Chem Chemother 19(4):165\u2013176","journal-title":"Antivir Chem Chemother"},{"issue":"6","key":"4725_CR102","doi-asserted-by":"publisher","first-page":"100354","DOI":"10.1016\/j.jhepr.2021.100354","volume":"3","author":"S Faure-Dupuy","year":"2021","unstructured":"Faure-Dupuy S et al (2021) Control of APOBEC3B induction and CccDNA decay by NF-kappaB and miR-138-5. JHEP Rep 3(6):100354","journal-title":"JHEP Rep"},{"issue":"2","key":"4725_CR103","doi-asserted-by":"publisher","first-page":"e0288821","DOI":"10.1128\/mbio.02888-21","volume":"13","author":"MG Martinez","year":"2022","unstructured":"Martinez MG et al (2022) CRISPR-Cas9 targeting of hepatitis B virus covalently closed circular DNA generates transcriptionally active episomal variants. mBio 13(2):e0288821","journal-title":"mBio"},{"key":"4725_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/genes9040207","author":"K Bloom","year":"2018","unstructured":"Bloom K et al (2018) Gene therapy for chronic HBV-can we eliminate cccDNA? Genes. https:\/\/doi.org\/10.3390\/genes9040207","journal-title":"Genes"},{"issue":"5","key":"4725_CR105","doi-asserted-by":"publisher","first-page":"e866","DOI":"10.1002\/iid3.866","volume":"11","author":"B Cai","year":"2023","unstructured":"Cai B et al (2023) CRISPR\/Cas9 for hepatitis B virus infection treatment. Immun Inflamm Dis 11(5):e866","journal-title":"Immun Inflamm Dis"},{"key":"4725_CR106","doi-asserted-by":"publisher","first-page":"1467449","DOI":"10.3389\/fgeed.2024.1467449","volume":"6","author":"ZQ Yao","year":"2024","unstructured":"Yao ZQ et al (2024) The potential of HBV cure: an overview of CRISPR-mediated HBV gene disruption. Front Genome Ed 6:1467449","journal-title":"Front Genome Ed"},{"issue":"1","key":"4725_CR107","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.virol.2006.09.006","volume":"359","author":"C Franke","year":"2007","unstructured":"Franke C, Matschl U, Bruns M (2007) Enzymatic treatment of duck hepatitis B virus: topology of the surface proteins for virions and noninfectious subviral particles. Virology 359(1):126\u2013136","journal-title":"Virology"},{"issue":"8","key":"4725_CR108","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","volume":"158","author":"M Bazinet","year":"2020","unstructured":"Bazinet M et al (2020) Safety and efficacy of 48 weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection Naive to Nucleos(t)ide therapy. Gastroenterology 158(8):2180\u20132194","journal-title":"Gastroenterology"},{"issue":"12","key":"4725_CR109","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","volume":"2","author":"M Bazinet","year":"2017","unstructured":"Bazinet M et al (2017) Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2(12):877\u2013889","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4725_CR110","doi-asserted-by":"publisher","first-page":"104917","DOI":"10.1016\/j.antiviral.2020.104917","volume":"182","author":"U Viswanathan","year":"2020","unstructured":"Viswanathan U et al (2020) Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B. Antiviral Res 182:104917","journal-title":"Antiviral Res"},{"key":"4725_CR111","doi-asserted-by":"crossref","unstructured":"Olenginski LT et al (2023) Hepatitis B virus epsilon (epsilon) RNA element: dynamic regulator of viral replication and attractive therapeutic target. Viruses, 15(9):1913","DOI":"10.3390\/v15091913"},{"issue":"1","key":"4725_CR112","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21505594.2022.2093444","volume":"13","author":"S Phillips","year":"2022","unstructured":"Phillips S, Jagatia R, Chokshi S (2022) Novel therapeutic strategies for chronic hepatitis B. Virulence 13(1):1111\u20131132","journal-title":"Virulence"},{"issue":"6","key":"4725_CR113","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP (2019) The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov 18(6):421\u2013446","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4725_CR114","first-page":"e0161","volume":"23","author":"RW Hui","year":"2024","unstructured":"Hui RW et al (2024) Therapeutic advances in HBV cure. Clin Liver Dis (Hoboken) 23(1):e0161","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"1","key":"4725_CR115","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12951-024-03004-3","volume":"22","author":"L Nguyen","year":"2024","unstructured":"Nguyen L et al (2024) Advanced SiRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates. J Nanobiotechnol 22(1):745","journal-title":"J Nanobiotechnol"},{"key":"4725_CR116","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0241","author":"CI Wooddell","year":"2017","unstructured":"Wooddell CI et al (2017) RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aan0241","journal-title":"Sci Transl Med"},{"issue":"1","key":"4725_CR117","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hep.31008","volume":"72","author":"MF Yuen","year":"2020","unstructured":"Yuen MF et al (2020) RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection. Hepatology 72(1):19\u201331","journal-title":"Hepatology"},{"issue":"1","key":"4725_CR118","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41392-024-02026-5","volume":"9","author":"HK Rachamala","year":"2024","unstructured":"Rachamala HK, Marepally S (2024) Multiplexed rnas in lipid nanoparticles: potential therapeutic vaccine for chronic hepatitis B. Signal Transduct Target Ther 9(1):312","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"4725_CR119","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"M-F Yuen","year":"2022","unstructured":"Yuen M-F et al (2022) Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med 387(21):1957\u20131968","journal-title":"N Engl J Med"},{"issue":"4","key":"4725_CR120","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/hep.31920","volume":"74","author":"E Gane","year":"2021","unstructured":"Gane E et al (2021) Clinical study of Single-Stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B. Hepatology 74(4):1795\u20131808","journal-title":"Hepatology"},{"key":"4725_CR121","unstructured":"Phase (2022) 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 2)"},{"issue":"11","key":"4725_CR122","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/13543784.2023.2277389","volume":"32","author":"LY Mak","year":"2023","unstructured":"Mak LY et al (2023) Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress. Expert Opin Investig Drugs 32(11):971\u2013983","journal-title":"Expert Opin Investig Drugs"},{"key":"4725_CR123","doi-asserted-by":"publisher","unstructured":"Sun L et al (2020) The Dihydroquinolizinone compound RG7834 inhibits the polyadenylase function of PAPD5 and PAPD7 and accelerates the degradation of matured hepatitis B virus surface protein mRNA. Antimicrob Agents Chemother 65(1). https:\/\/doi.org\/10.1128\/aac.00640-20","DOI":"10.1128\/aac.00640-20"},{"key":"4725_CR124","doi-asserted-by":"publisher","first-page":"114518","DOI":"10.1016\/j.ejmech.2022.114518","volume":"238","author":"X Qin","year":"2022","unstructured":"Qin X et al (2022) Identification of Dihydroquinolizinone derivatives with Cyclic ether moieties as new anti-HBV agents. Eur J Med Chem 238:114518","journal-title":"Eur J Med Chem"},{"issue":"5","key":"4725_CR125","doi-asserted-by":"publisher","first-page":"e00094","DOI":"10.1128\/aac.00094-22","volume":"66","author":"X Li","year":"2022","unstructured":"Li X et al (2022) Safety, Tolerability, and pharmacokinetics of the novel hepatitis B virus expression inhibitor GST-HG131 in healthy Chinese subjects: a First-in-Human Single- and Multiple-Dose escalation trial. Antimicrob Agents Chemother 66(5):e00094\u2013e00022","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"4725_CR126","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1021\/acsmedchemlett.1c00228","volume":"12","author":"N Hwang","year":"2021","unstructured":"Hwang N et al (2021) Hepatoselective Dihydroquinolizinone Bis-acids for HBsAg mRNA degradation. ACS Med Chem Lett 12(7):1130\u20131136","journal-title":"ACS Med Chem Lett"},{"issue":"7594","key":"4725_CR127","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nature17170","volume":"531","author":"A Decorsi\u00e8re","year":"2016","unstructured":"Decorsi\u00e8re A et al (2016) Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor. Nature 531(7594):386\u2013389","journal-title":"Nature"},{"key":"4725_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13121100","volume":"13","author":"W He","year":"2024","unstructured":"He W et al (2024) Targeting HBV cccDNA levels: key to achieving complete cure of chronic hepatitis B. Pathogens 13:1100. https:\/\/doi.org\/10.3390\/pathogens13121100","journal-title":"Pathogens"},{"issue":"4","key":"4725_CR129","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11901-016-0315-9","volume":"15","author":"EA Pham","year":"2016","unstructured":"Pham EA et al (2016) Future therapy for hepatitis B virus: role of immunomodulators. Curr Hepatol Rep 15(4):237\u2013244","journal-title":"Curr Hepatol Rep"},{"key":"4725_CR130","doi-asserted-by":"publisher","first-page":"1363996","DOI":"10.3389\/fimmu.2024.1363996","volume":"15","author":"S Soleiman-Meigooni","year":"2024","unstructured":"Soleiman-Meigooni S et al (2024) Recent advances in different interactions between toll-like receptors and hepatitis B infection: a review. Front Immunol 15:1363996","journal-title":"Front Immunol"},{"issue":"2","key":"4725_CR131","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","volume":"63","author":"EJ Gane","year":"2015","unstructured":"Gane EJ et al (2015) The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol 63(2):320\u2013328","journal-title":"J Hepatol"},{"issue":"9","key":"4725_CR132","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/jmv.24809","volume":"89","author":"M Jones","year":"2017","unstructured":"Jones M et al (2017) SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol 89(9):1620\u20131628","journal-title":"J Med Virol"},{"key":"4725_CR133","first-page":"191","volume":"58","author":"RS Schulof","year":"1981","unstructured":"Schulof RS et al (1981) Thymosins and other hormones of the thymus gland. Prog Clin Biol Res 58:191\u2013215","journal-title":"Prog Clin Biol Res"},{"issue":"2","key":"4725_CR134","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","volume":"138","author":"P Fisicaro","year":"2010","unstructured":"Fisicaro P et al (2010) Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138(2):682\u2013693 693 e1-4","journal-title":"Gastroenterology"},{"issue":"4","key":"4725_CR135","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3350\/cmh.2024.0058","volume":"30","author":"X Wan","year":"2024","unstructured":"Wan X et al (2024) Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting. Clin Mol Hepatol 30(4):735\u2013755","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"4725_CR136","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3350\/cmh.2025.0492","volume":"31","author":"CL Lin","year":"2025","unstructured":"Lin CL, Kao JH (2025) Global strategies and actions to eliminate hepatitis B virus infection. Clin Mol Hepatol 31(4):1197\u20131212","journal-title":"Clin Mol Hepatol"},{"issue":"Suppl 1","key":"4725_CR137","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/liv.14848","volume":"41","author":"M Buti","year":"2021","unstructured":"Buti M, Marcos-Fosch C, Esteban R (2021) Nucleos(t)ide analogue therapy: the role of Tenofovir Alafenamide. Liver Int 41(Suppl 1):9\u201314","journal-title":"Liver Int"},{"issue":"3","key":"4725_CR138","doi-asserted-by":"publisher","first-page":"106446","DOI":"10.1016\/j.jinf.2025.106446","volume":"90","author":"M Zhang","year":"2025","unstructured":"Zhang M et al (2025) Efficacy and safety of GLS4 with Entecavir vs Entecavir alone in chronic hepatitis B patients: A multicenter clinical trial. J Infect 90(3):106446","journal-title":"J Infect"},{"issue":"4","key":"4725_CR139","doi-asserted-by":"publisher","first-page":"105797","DOI":"10.4254\/wjh.v17.i4.105797","volume":"17","author":"T Liu","year":"2025","unstructured":"Liu T et al (2025) Drug development for chronic hepatitis B functional cure: recent progress. World J Hepatol 17(4):105797","journal-title":"World J Hepatol"},{"issue":"1","key":"4725_CR140","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa2213429","volume":"389","author":"H Wedemeyer","year":"2023","unstructured":"Wedemeyer H et al (2023) A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med 389(1):22\u201332","journal-title":"N Engl J Med"},{"key":"4725_CR141","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/DDDT.S379964","volume":"17","author":"V Soriano","year":"2023","unstructured":"Soriano V et al (2023) Bulevirtide in the treatment of hepatitis delta: drug Discovery, clinical development and place in therapy. Drug Des Devel Ther 17:155\u2013166","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"4725_CR142","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jhep.2022.09.027","volume":"78","author":"EJ Gane","year":"2023","unstructured":"Gane EJ et al (2023) Safety and efficacy of the oral TLR8 agonist Selgantolimod in individuals with chronic hepatitis B under viral suppression. J Hepatol 78(3):513\u2013523","journal-title":"J Hepatol"},{"issue":"6","key":"4725_CR143","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","volume":"154","author":"C Boni","year":"2018","unstructured":"Boni C et al (2018) TLR7 agonist increases responses of hepatitis B Virus-Specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(T)ide analogues. Gastroenterology 154(6):1764-1777e7","journal-title":"Gastroenterology"},{"issue":"2","key":"4725_CR144","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/cid\/ciaa961","volume":"73","author":"H Zhang","year":"2021","unstructured":"Zhang H et al (2021) Antiviral activity and pharmacokinetics of the hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection. Clin Infect Dis 73(2):175\u2013182","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4725_CR145","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","volume":"159","author":"F Zoulim","year":"2020","unstructured":"Zoulim F et al (2020) JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection. Gastroenterology 159(2):521-533e9","journal-title":"Gastroenterology"},{"issue":"4","key":"4725_CR146","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/cpdd.318","volume":"6","author":"T Schluep","year":"2017","unstructured":"Schluep T et al (2017) Safety, Tolerability, and pharmacokinetics of ARC-520 Injection, an RNA Interference-Based therapeutic for the treatment of chronic hepatitis B virus Infection, in healthy volunteers. Clin Pharmacol Drug Dev 6(4):350\u2013362","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4725_CR147","doi-asserted-by":"publisher","first-page":"1128807","DOI":"10.3389\/fcimb.2023.1128807","volume":"13","author":"Y Pan","year":"2023","unstructured":"Pan Y et al (2023) The progress of molecules and strategies for the treatment of HBV infection. Front Cell Infect Microbiol 13:1128807","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"4725_CR148","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1021\/acsinfecdis.4c00514","volume":"10","author":"EP Thi","year":"2024","unstructured":"Thi EP et al (2024) Control of hepatitis B virus with Imdusiran, a small interfering RNA therapeutic. ACS Infect Dis 10(10):3640\u20133649","journal-title":"ACS Infect Dis"},{"issue":"23","key":"4725_CR149","doi-asserted-by":"publisher","first-page":"21126","DOI":"10.1021\/acs.jmedchem.4c01814","volume":"67","author":"S Vendeville","year":"2024","unstructured":"Vendeville S et al (2024) The discovery and preclinical profile of ALG-000184, a prodrug of the potent hepatitis B virus capsid assembly modulator ALG-001075. J Med Chem 67(23):21126\u201321142","journal-title":"J Med Chem"},{"key":"4725_CR150","unstructured":"A Phase 1, Open-Label, First-in-Human, Dose Escalation (Part 1) and Expansion (Part 2) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of PBGENE-HBV in Participants With Chronic Hepatitis B (ELIMINATE-B). (2024)"},{"issue":"4","key":"4725_CR151","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","volume":"20","author":"SG Lim","year":"2023","unstructured":"Lim SG et al (2023) The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Reviews Gastroenterol Hepatol 20(4):238\u2013253","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"2","key":"4725_CR152","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.gtc.2020.01.003","volume":"49","author":"E Spyrou","year":"2020","unstructured":"Spyrou E, Smith CI, Ghany MG (2020) Hepatitis b: current status of therapy and future therapies. Gastroenterol Clin North Am 49(2):215\u2013238","journal-title":"Gastroenterol Clin North Am"},{"key":"4725_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/v14020434","author":"RN Chien","year":"2022","unstructured":"Chien RN, Liaw YF (2022) Current trend in antiviral therapy for chronic hepatitis B. Viruses. https:\/\/doi.org\/10.3390\/v14020434","journal-title":"Viruses"},{"key":"4725_CR154","doi-asserted-by":"crossref","unstructured":"Rahatullah HS (2025) Current and emerging therapeutic strategies for chronic hepatitis B virus infection: A review. Eur J Med Health Sci, 7(3): 1\u20139","DOI":"10.24018\/ejmed.2025.7.3.2280"},{"issue":"3","key":"4725_CR155","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jhepr.2019.06.001","volume":"1","author":"S Ferrando-Martinez","year":"2019","unstructured":"Ferrando-Martinez S et al (2019) HBeAg seroconversion is associated with a more effective PD-L1 Blockade during chronic hepatitis B infection. JHEP Rep 1(3):170\u2013178","journal-title":"JHEP Rep"},{"key":"4725_CR156","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000496","author":"J Lok","year":"2023","unstructured":"Lok J, Dusheiko G (2023) Reassessing antiviral treatment criteria for chronic hepatitis B. Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000000496","journal-title":"Hepatology"},{"issue":"6","key":"4725_CR157","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000525518","volume":"11","author":"SK Kim","year":"2022","unstructured":"Kim SK et al (2022) Hepatitis B virus treatment and hepatocellular carcinoma: controversies and approaches to consensus. Liver Cancer 11(6):497\u2013510","journal-title":"Liver Cancer"},{"issue":"1","key":"4725_CR158","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/cco-20-46","volume":"10","author":"TP Hang","year":"2021","unstructured":"Hang TP, Wedd JP (2021) The optimal timing and management of hepatitis B and C in patients with hepatocellular carcinoma. Chin Clin Oncol 10(1):4","journal-title":"Chin Clin Oncol"},{"key":"4725_CR159","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2180-8-11","volume":"8","author":"M Bottecchia","year":"2008","unstructured":"Bottecchia M et al (2008) Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil. BMC Microbiol 8:11","journal-title":"BMC Microbiol"},{"key":"4725_CR160","doi-asserted-by":"crossref","unstructured":"Tang S et al (2025) EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection. GutOct 28:gutjnl-2025-335449","DOI":"10.1136\/gutjnl-2025-335449"},{"issue":"4","key":"4725_CR161","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/apt.13707","volume":"44","author":"S Lingala","year":"2016","unstructured":"Lingala S et al (2016) Long-term lamivudine therapy in chronic hepatitis B. Aliment Pharmacol Ther 44(4):380\u2013389","journal-title":"Aliment Pharmacol Ther"},{"key":"4725_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/v15112241","author":"C Henriquez-Camacho","year":"2023","unstructured":"Henriquez-Camacho C et al (2023) Lamivudine and entecavir for acute hepatitis B: a systematic review and meta-analysis. Viruses. https:\/\/doi.org\/10.3390\/v15112241","journal-title":"Viruses"},{"key":"4725_CR163","doi-asserted-by":"crossref","unstructured":"Ignat MD et al (2024) Antiviral therapy of chronic hepatitis B virus between present and future. J Clin Med, 13(7):2055","DOI":"10.3390\/jcm13072055"},{"key":"4725_CR164","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.213969","author":"Y-D Xie","year":"2017","unstructured":"Xie Y-D et al (2017) Efficacy of real-world entecavir therapy in treatment-na\u00efve chronic hepatitis B patients. Chin Med J. https:\/\/doi.org\/10.4103\/0366-6999.213969","journal-title":"Chin Med J"},{"key":"4725_CR165","doi-asserted-by":"publisher","first-page":"232595822091923","DOI":"10.1177\/2325958220919231","volume":"19","author":"C Wassner","year":"2020","unstructured":"Wassner C, Bradley N, Lee Y (2020) A review and clinical Understanding of tenofovir: Tenofovir disoproxil fumarate versus Tenofovir Alafenamide. J Int Assoc Provid AIDS Care 19:2325958220919231","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"1","key":"4725_CR166","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jceh.2020.05.003","volume":"11","author":"MK Behera","year":"2021","unstructured":"Behera MK et al (2021) Tenofovir is superior to Entecavir in patients with Treatment-na\u00efve hepatitis B e-Antigen-Positive chronic hepatitis B. J Clin Exp Hepatol 11(1):37\u201344","journal-title":"J Clin Exp Hepatol"},{"issue":"9","key":"4725_CR167","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/jgh3.12636","volume":"5","author":"K Inada","year":"2021","unstructured":"Inada K et al (2021) Tenofovir Alafenamide for prevention and treatment of hepatitis B virus reactivation and de Novo hepatitis. JGH Open 5(9):1085\u20131091","journal-title":"JGH Open"},{"issue":"4","key":"4725_CR168","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1111\/jvh.12025","volume":"20","author":"Y Wang","year":"2013","unstructured":"Wang Y et al (2013) Efficacy and safety of continuous 4-year Telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat 20(4):e37\u201346","journal-title":"J Viral Hepat"},{"key":"4725_CR169","doi-asserted-by":"publisher","first-page":"105782","DOI":"10.1016\/j.antiviral.2023.105782","volume":"221","author":"Q Zhao","year":"2024","unstructured":"Zhao Q et al (2024) Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy. Antiviral Res 221:105782","journal-title":"Antiviral Res"},{"issue":"5","key":"4725_CR170","doi-asserted-by":"publisher","first-page":"e0269424","DOI":"10.1128\/spectrum.02694-24","volume":"13","author":"H Liang","year":"2025","unstructured":"Liang H et al (2025) Comparative efficacy and safety of pegylated interferon-alpha monotherapy vs combination therapies with Entecavir or Tenofovir in chronic hepatitis B patients. Microbiol Spectr 13(5):e0269424","journal-title":"Microbiol Spectr"},{"issue":"5","key":"4725_CR171","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1111\/j.1523-1755.2005.00689.x","volume":"68","author":"NK Tong","year":"2005","unstructured":"Tong NK et al (2005) Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and Hemodialysis patients. Kidney Int 68(5):2298\u20132303","journal-title":"Kidney Int"},{"issue":"15","key":"4725_CR172","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1016\/j.vaccine.2006.01.007","volume":"24","author":"P Rendi-Wagner","year":"2006","unstructured":"Rendi-Wagner P et al (2006) Comparative immunogenicity of a PreS\/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 24(15):2781\u20132789","journal-title":"Vaccine"},{"issue":"5947","key":"4725_CR173","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/307178a0","volume":"307","author":"WJ McAleer","year":"1984","unstructured":"McAleer WJ et al (1984) Human hepatitis B vaccine from Recombinant yeast. Nature 307(5947):178\u2013180","journal-title":"Nature"},{"issue":"5725","key":"4725_CR174","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/280815a0","volume":"280","author":"P Valenzuela","year":"1979","unstructured":"Valenzuela P et al (1979) Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Nature 280(5725):815\u2013819","journal-title":"Nature"},{"key":"4725_CR175","doi-asserted-by":"crossref","unstructured":"Romano L, Zanetti AR (2022) Hepatitis B vaccination: A historical overview with a focus on the Italian achievements. Viruses, 14(7):1515","DOI":"10.3390\/v14071515"},{"issue":"2","key":"4725_CR176","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.imlet.2015.10.007","volume":"168","author":"D Yu","year":"2015","unstructured":"Yu D et al (2015) A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV Transgenic mice. Immunol Lett 168(2):293\u2013299","journal-title":"Immunol Lett"},{"issue":"7","key":"4725_CR177","doi-asserted-by":"publisher","first-page":"10482","DOI":"10.1021\/acsnano.2c01283","volume":"16","author":"M Li","year":"2022","unstructured":"Li M et al (2022) Virus-Like Particle-Templated Silica-Adjuvanted nanovaccines with enhanced humoral and cellular immunity. ACS Nano 16(7):10482\u201310495","journal-title":"ACS Nano"},{"issue":"2","key":"4725_CR178","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1053\/j.gastro.2018.10.032","volume":"156","author":"AJ Gehring","year":"2019","unstructured":"Gehring AJ, Protzer U (2019) Targeting innate and adaptive immune responses to cure chronic HBV infection. Gastroenterology 156(2):325\u2013337","journal-title":"Gastroenterology"},{"issue":"12","key":"4725_CR179","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1136\/gutjnl-2014-308041","volume":"64","author":"P Martin","year":"2015","unstructured":"Martin P et al (2015) TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut 64(12):1961\u20131971","journal-title":"Gut"},{"issue":"1","key":"4725_CR180","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41541-024-00813-3","volume":"9","author":"H Zhao","year":"2024","unstructured":"Zhao H et al (2024) A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. Npj Vaccines 9(1):22","journal-title":"Npj Vaccines"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-026-04725-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-026-04725-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-026-04725-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:08:06Z","timestamp":1772024886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-026-04725-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":180,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4725"],"URL":"https:\/\/doi.org\/10.1007\/s00284-026-04725-4","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"151"}}